Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13464973 | 1.00 | OPRM1 (0.42) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12448267 | 0.85 | SLC6A2 (0.40) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8011446 | 0.81 | PRCP (0.56) | PRCP | |
| SCHEMBL4737669 | 0.79 | PRCP (0.40) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2706549 | 0.79 | PRCP (0.40) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20055229 | 0.77 | PRCP (0.43) | OPRM1OPRK1PRCPKDM4EMEN1 | |
| SCHEMBL18559580 | 0.74 | SLC6A2 (0.46) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11997024 | 0.74 | SLC6A2 (0.46) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10278431 | 0.74 | SLC6A2 (0.46) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11824939 | 0.73 | OPRM1 (0.47) | OPRM1OPRK1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| WO-2019171358-A1 | RELEASABLE ANTIBODY CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2019-09-12 | — | — | WO | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-8168798-B2 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-7842324-B2 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | TRANSTECH PHARMA, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | TRANSTECH PHARMA, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| US-20070003680-A1 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | AGER, APP, BACE1 | OPRM1 3185/4885OPRK1 2818/4885SLC6A2 1606/4885 |
| US-20110137037-A1 | CASPASE INHIBITOR PRODRUGS | CASP1, CASP5, CASP2 | OPRM1 4059/4885OPRK1 3954/4885SLC6A2 4775/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | OPRM1 3220/4885OPRK1 3141/4885SLC6A2 3456/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | OPRM1 3220/4885OPRK1 3141/4885SLC6A2 3456/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | OPRM1 3220/4885OPRK1 3141/4885SLC6A2 3456/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | OPRM1 857/4885OPRK1 636/4885SLC6A2 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.